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 FOREWORD 
 
The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
and Trusts Chief Executives (HATCH) and the Trent Development and Evaluation 
Committee (DEC). A public health consultant from a purchasing authority leads on each 
topic assisted by a support team from ScHARR, which provides help including literature 
searching, health economics and modelling. A seminar is led by the public health consultant 
on the particular intervention where purchasers and provider clinicians consider research 
evidence and agree provisional recommendations on purchasing policy. The guidance 
emanating from the seminars is reflected in this series of Guidance Notes which have been 
reviewed by the Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
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Chairman, Trent Working Group on Acute Purchasing 
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EXECUTIVE SUMMARY 
 
It is estimated that the number of people with dementia in a ‘typical’ district health authority 
population of 500,000 is approximately 5,700, of whom around 3,000 are likely to have mild 
to moderate Alzheimer’s disease or vascular dementia.  
 
Propentofylline is the first of the new dementia drugs to have sought an approval for use in 
dementia of vascular origin, although this may be due to lack of studies with other drugs 
rather than a specific pharmacological action of propentofylline. On 20 October 1998 the 
Committee for Proprietary Medicinal Products (CPMP) of the European Medicines 
Evaluation Agency (EMEA) voted not to recommend marketing authorisation in the 
European Union. It is unclear whether an appeals procedure will be invoked but, in any 
case, it is now unlikely that this product will come to market before the end of 1999. The 
potential cost of propentofylline in the UK has not yet been released, however, an economic 
impact model for Sweden at 1991 prices, authored by pharmaceutical company employees, 
indicated a target price in the region of £350 per patient per year. Thus, if all potential 
patients received therapy, this would indicate a total cost to a health authority of around £1.1 
million. 
 
Evidence of efficacy is based on one published randomised controlled trial of 260 patients  
together with two published meta-analyses of the Phase III programme. The Phase III 
programme includes three further unpublished trials, bringing the total number of trial 
patients up to 1,273. Several assessment scales were reported in the trials; these 
addressed global function, cognitive function and activities of daily living. The Phase III 
programme was initiated before the widespread availability of the Alzheimer’s Disease 
Assessment Scale (ADAS), and the scales used in the trials are not widely used or widely 
known in the UK. The trials examined the effects of propentofylline over a 12 month period 
and an eight week extension study examined the response to withdrawal. 
 
The results of the trials showed very modest improvements in global function, cognitive 
function and activities of daily living. The improvements were statistically significant, but of 
very doubtful clinical relevance. The quality of life for patients or carers was not examined in 
the trials. It should be recognised that quality of life assessment instruments have not yet 
been validated in this patient group.  
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The precise mode of action is, as yet, uncertain. However, the eight week withdrawal study, 
referred to above, suggests that the effects may be sustained following withdrawal, which 
would support the proposition that the drug may prevent disease progression rather than 
just provide symptomatic benefit. 
 
The total cost includes the cost of the drug and the cost of a potential increase in demand 
for specialist assessment and diagnosis. There is no empirical evidence to suggest that 
drug therapy would result in a delay to the progression of the disease and thereby lead to 
savings in the NHS or other agencies. Modelling of the economic impact of drug therapy has 
been undertaken and shows a benefit in favour of propentofylline. This modelling, however, 
is based on an assumed relationship between small changes in cognitive function and care 
requirement, which is not supported by firm evidence or by independent clinical expert 
judgement. 
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1. INTRODUCTION 
 
This Guidance Note for propentofylline is the second in a series of evaluations of new drugs 
in dementia. The manufacturer of propentofylline is Hoechst Marion Roussel (HMR) and the 
proposed trade name is ViviQ. Parts of the report draw heavily on an earlier review of 
donepezil
1
 but, for completeness, are repeated here in full. 
 
It should be noted that propentofylline has been described as indicated for both vascular 
dementia (VaD) and Alzheimer’s disease (AD); the potential target population is, therefore, 
larger than for donepezil, which is licensed specifically for AD. 
 
1.1 Incidence and Pathology 
 
Overall, dementia is a major cause of disability amongst older adults. It affects about 8% of 
people over 65 years of age, rising to over 20% in the over 80s. Approximately 70% of 
cases of dementia are due to AD and a further 20% fall into the category of VaD; 60% of all 
cases have mild to moderate disease. 
 
The most recent compilation of prevalence data for dementia comes from the work of 
EURODEM,
2 
the European Commission for Concerted Action on the Epidemiology and 
Prevention of Dementia. EURODEM has published age and sex specific prevalence 
estimates for dementia derived from 12 European population-based studies conducted or 
published since 1980. These studies have all had sample sizes sufficiently large to enable 
age and sex specific estimates of prevalence to be calculated with some precision. 
 
The prevalence rate for dementia from the EURODEM study implies that there would be 
approximately 5,725 cases of dementia in a ‘typical’ district of 500,000 population, see  
Table 1. Assuming that AD is responsible for approximately 70% and vascular dementia for 
20% of dementia cases in older adults, we would expect about 3,100 cases of mild and 
moderate disease which might be suitable for treatment with propentofylline. 
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Table 1  The Prevalence of Dementia Applied to a Population of 500,000  
Age Population Prevalence Expected Mild and Mild and Mild and
Group of Dementia Dementia Moderate Moderate Moderate
Male Female AD VaD Total
45-64 112,756 0.1% 0.1% 68 28 8 37
65-69 24,184 2.2% 1.1% 393 165 47 212
70-74 22,022 4.6% 3.9% 928 390 111 501
75-79 15,056 5.0% 6.7% 906 380 109 489
80-84 10,838 12.1% 13.5% 1,411 592 169 762
85+ 8,079 21.5% 26.2% 2,020 849 242 1091
Total 45+ 192,935 5,725 2,405 687 3,092
All ages 500,000
 
 
The incidence rate of new cases of dementia is estimated to be 1% per annum in people 
aged 65 or over, and increases with age. It would be expected that there would be 800 new 
cases of dementia in the ‘typical’ district each year, with about 560 and 160 of these being of 
the Alzheimer's and vascular types respectively. 
 
1.2 Prognosis and Mortality 
 
Originally, all dementia was thought to be caused by vascular lesions.  However, senile 
dementia of the Alzheimer's type, is now generally considered to be distinct from VaD.  
Histopathological studies indicate that vascular pathology is the sole cause of symptoms in 
9-33% of patients with dementia and contributes to dementia in a further 10-36% of cases.  
Vascular dementia is probably the second commonest type of dementia after AD, and may 
be the commonest type in patients over the age of 85. 
 
It was once thought that cerebro-arteriosclerotic changes were the fundamental lesions until 
Hachinski,
3
 in 1994, concluded that when VaD was responsible for dementia it was not 
directly the result of cerebral arteriosclerosis, but as a result of multiple infarcts, secondary 
to embolic disease from extra-cranial arteries and the heart.  Therefore, the term multi-
infarct dementia was adopted. It has been realised since that ischaemic lesions can occur 
without evidence of infarction and that, in some cases, haemorrhage is the important 
mechanism. It has also been shown that ischaemia of the sub-cortical white matter may be 
the commonest mechanism. The white matter is especially vulnerable, because it is supplied 
by long penetrating end arterioles from the surface and base of the brain. Initially, it was 
thought that the quantity of cerebral softening (indicative of ischaemia) proportionally 
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accorded with the severity of the dementia with a threshold effect apparent.  It has since 
been shown that a single strategically sited lesion, for example, in the inferior parietal lobe, 
can cause dementia. Stroke and age are the most important risk factors for VaD and a 
symptomatic stroke increases the risk of dementia more than nine-fold. 
 
The term Vascular Dementia has been adopted by the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM IV), whilst in the 10
th
 edition of the International 
Classification of Diseases (ICD10), VaD is sub-classified into VaD of acute onset, multi-
infarct dementia, sub-cortical VaD and mixed or unspecified types. 
 
The Hachinski lschaemic Scale is widely used for research purposes. VaD is diagnosed 
when the patient is given a score of seven or higher. The scale has poor inter-rater reliability 
and modified versions have been proposed. 
 
More recently, two new sets of criteria have been formulated by: 
 
 The State of California Alzheimer’s Disease Diagnostic and Treatment Centre 
(ADDTC); 
 
 The National Institute of Neurological Disorders and Stroke and European Panel of 
Experts (NINDS - AIREN). 
 
Both require the presence of: 
 
 dementia; 
 
 cerebrovascular disease; 
 
 a relation between the two. 
 
These scales may be more sensitive than the Hachinski Scale, although validation studies 
on post mortem examinations are awaited. All the above are based on the multi-infarct 
concept of VaD, except for the ICD10 and the NINDS-AIREN. 
 
Pathologically, atrophy and ventricular enlargement is seen as in AD, but with the additional 
changes of cerebral softening due to intercranial infarcts and haemorrhages. These 
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changes can be seen in vivo on a Computed Tomography (CT) scan and more clearly on a 
Magnetic Resonance Imaging (MRI) scan, which may also show white matter lesions more 
clearly. 
 
Positron emission tomography (PET) shows functional as opposed to morphological 
changes.  It can distinguish multi-infarct dementia from AD by showing a characteristic area 
of hypo-metabolism. 
 
Once the diagnosis of VaD has been made, special attention should be given to: 
 
 detection of vascular risk factors, including hypertension and diabetes; 
 
 examination of the cardiovascular system, with particular regard to the causes of 
thromboembolism, including atrial fibrillation, valvular heart disease and carotid stenosis; 
 
 exclusion of other treatable causes of dementia, such as, endocrine disorders and 
vitamin deficiencies. 
 
Treatment is aimed at reducing the risk of further damage by the treatment of associated 
cardiovascular disease, and prophylaxis against thrombosis by the use of anti-platelet drugs 
and anticoagulants. Treatment of hypercholesterolaemia and advice and support about 
stopping smoking is also important. Those with substantial carotid stenosis should be 
considered for surgery. Patients with vasculitis may benefit from immuno-suppressive drugs. 
Previously, neuro-metabolic treatments have not been shown to be clinically useful. 
 
Symptomatic treatments such as tranquillisers and hypnotics often have to be considered 
and depression is common, probably because insight is often retained. Therefore, 
antidepressants are commonly used. 
 
The course and survival rate in VaD are much less predictable than in AD with potentially 
great individual variability. The onset is typically abrupt followed by a stepwise and 
fluctuating course, and is characterised by rapid changes in functioning rather than slow 
progression. However, an insidious onset with gradual decline, associated with ‘silent’ 
infarcts, may also be encountered. Treatment of hypertension and other risk factors may 
alter the course and prevent further progression. Comparative studies have found a slightly 
better two year survival average than in AD, but five year studies have not shown a 
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significant difference. There may be slightly better prospects for females. Death is 
commonly attributed to ischaemic heart disease. In VaD, focal neurological signs are often 
present, in association with other evidence of VaD. This can be contrasted with the insidious 
and gradual onset of dementia in AD, which is characterised by a more consistent and 
widespread impairment consisting of amnesia, dysphasia, dyspraxia and agnosia. The 
course of AD tends to be slowly progressive with, for example, a deterioration of three - four 
points per year on the serial Mini Mental State Examination (MMSE). The average duration 
of illness from onset of symptoms to death is eight to ten years. Although, clinicians have 
reported cases of AD which appear to plateau for significant periods of time, this is not 
characteristic. Unfortunately, post-mortem validation of such cases is not often pursued. 
Therefore, for clinical purposes, a patient in whom the course of the dementia is not 
progressive should not be considered to have AD. Females with AD tend to survive longer 
following diagnosis, but the reason for this is open to speculation. It may be that male 
demented patients tend to be in relatively poorer physical condition generally. Most people 
with severe AD die of intercurrent illness, particularly broncho-pneumonia. However, some 
patients seem to ‘fade away’ over a period of several weeks without any specific reason 
being found at post-mortem other than AD.  
 
1.3 The Mode of Action of Propentofylline 
 
Propentofylline has a different pharmacological basis for use in dementia than the two 
existing drugs, donepezil and rivastigmine.  The latter are both cholinesterase inhibitors, 
which have predominantly central effects with limited peripheral activity, hence minimising 
toxicity. Other drugs yet to reach the market, in the UK or elsewhere, are likely to have 
various pharmacological activities; these are summarised in Table 2 below. 
 
Table 2 Summary of New Drugs in Dementia and their Modes of Action 
Propentofylline Phosphodiesterase inhibitor 
Adenosine re-uptake inhibitor 
Galantamine Cholinesterase inhibitor 
Metriphonate Cholinesterase inhibitor 
Milameline Muscarinic receptor antagonist 
Nefiracetam GABA receptor antagonist 
Sabeluzole Calcium channel antagonist 
Xanomeline Muscarinic M1 & M4 antagonist 
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Propentofylline, however, is a phosphodiesterase inhibitor (c.f. theophylline, caffeine) and an 
adenosine re-uptake inhibitor. The relative and absolute significance of these activities in 
dementia is not fully substantiated.  It appears to limit the action of glial cells in the brain by 
preventing the enzymatic breakdown of cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP) through inhibition of cyclic nucleotide 
phosphodiesterases.  cAMP and cGMP are thought to have important roles in the regulation 
of neural function. Propentofylline also limits the re-uptake of adenosine, resulting in 
extracellular accumulation, which is considered to potentiate its neuroprotective effects 
mediated by adenosine A1 and A2 receptors.
4
 
 
There is also some evidence that propentofylline reduces neuronal damage caused by 
ischaemia and inhibits potentially neurotoxic properties of activated microglial cells.  It may 
also promote brain tissue repair by enhancing the synthesis and release of neurotrophin 
nerve growth factor (NGF) from astroglial cells and increase NGF content in the aged brain.
4
 
 
1.4 Scale of Problem in a ‘Typical’ District 
 
A prevalence of approximately 3,100 cases of mild to moderate dementia would be 
expected in a ‘typical’ district health authority population of 500,000. The price of 
propentofylline in the UK has not as yet been released. However, an economic evaluation
5
 
undertaken by employees of HMR, set in Sweden and priced at 1991 levels, quotes a daily 
price of SEK13; this would indicate a very approximate price of £1 per day. On this basis, 
the annual cost of treatment per patient might be expected to be around £350. Thus, if all 
potential patients in a district are treated, then the total annual cost of treatment to the 
district would be in the region of £1.1million. 
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2.  USE OF PROPENTOFYLLINE IN THE TREATMENT OF DEMENTIA: 
SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1  Available Evidence 
 
Eight randomised controlled trials (RCTs), which address the clinical effectiveness of 
propentofylline, have been identified through a systematic search of the published and grey 
literature. The trials are summarised in Table 3. 
 
Table 3  Randomised Controlled Trials of Propentofylline 
 
Trial Number 
in Study 
Lead Author Publication Status 
Pilot study 30 Mielke R Published
6,7
 
Phase II 190 Moller HJ Published
8
 
Phase III - Study I 293 -- Unpublished Included in  
Phase III - Study II 260 Marcusson J  Published
9
 ‘meta-analyses’ 
by Kittner
10
 &  
Phase III - Study III 170 -- Unpublished Rother
11
 
Phase III - Study IV 550 (Karlsson et al.) Unpublished  
Study 304 (AD) 486 Rother M  Conference poster
12
 
Study 305 (VaD) 454 Pischel T  Conference poster
13
 
 
 
The Phase III trial reported by Marcusson
9
 is included in the Kittner ‘meta-analysis’,
10 
and 
also the Rother paper,
11
 where it is referenced. This, therefore, leaves three further Phase 
III trials which have not been fully published. Full details of inclusion and exclusion criteria, 
drop-outs and adverse events from each of the trials are not available from the meta-
analyses. These issues mean that it is impossible adequately to critically appraise the meta-
analyses, as details of three of the four trials have to be taken on trust; the results and the 
conclusions drawn from the analyses must, therefore, be open to question. 
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A literature search was undertaken, based on the medical and health databases: including 
MEDLINE; EMBASE; HEALTHSTAR, the Cochrane Collaboration Trials Register, the NHS 
CRD DARE database and the NHS Economic Evaluation database, together with 
examination of the relevant health technology assessment agency resources: such as, web 
sites and booklets. Search terms were based on ‘propentofylline’, ‘HWA285’ and the CAS 
registry number. 
 
2.2 Outcome Measures 
 
The Phase III trials used a battery of tests and assessment scales. The primary outcome 
measures are the Gottfries-Bråne-Steen (GBS) scale, the Clinical Global Impression (CGI), 
and the Syndrome Short Test (SKT). The secondary outcome measures were the Mini 
Mental State Examination (MMSE), Nürnburger-Alters-Beobachtungs-Skala (NAB), Zerssen 
Adjective Mood Scale (BfS: Befindlichkeitsskala) and Digit Symbol Substitution Test 
(DSST). With the exception of the MMSE, these are not widely used assessment scales and 
are not in active use within the Trent Region or the UK in general. It is not possible to 
comment on their clinical relevance, other than by reference to the published literature. 
Therefore, a brief introduction to the scales is included below, based on either original 
publications or on background information given in the Marcusson paper.
9
  
 
The two trials detailed in the poster presentations to the International Conference on 
Alzheimer’s Disease and Related Disorders
12,13
 use the more widely known and accepted 
Alzheimer’s Disease Assessment Scale - Cognitive subscale (ADAS-cog) and the Clinician 
Interview Based Impression (CIBIC plus) assessment scales. 
 
Primary Outcome Variables in the Phase III trials 
 
1. The Gottfries-Bråne-Steen (GBS)
14
 scale uses a 7-step scoring system to measure 
motor function, intellectual function, emotional function and additional symptoms. 
The score ranges from 0 to 156 points and an increase indicates a deterioration in 
condition. 
 
2. The Clinical Global Impression (CGI) scale comprises two items each measured on a 
scale from 0 to 7 points. Item I measures severity of illness and item II measures 
global improvement compared to the previous assessment - note that only item II is 
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used in the primary efficacy measure. An increase in score indicates a deterioration 
in condition. 
 
3. The Syndrome Short Test (SKT; Syndrom Kurztest)
15
 measures impairment of 
memory, attention, speech and mental agility by means of a 4-step scoring system 
which is standardised for age and premorbid IQ. Parallel forms are used to avoid 
learning effects. The total score ranges from 0 to 27 points where an increase in 
score indicates a deterioration in condition. 
 
Secondary Outcome Variables in the Phase III Trials 
 
1. The Mini Mental State Examination (MMSE)
16
 is a well established measure for 
distinguishing between organic and functional illness in older adults. It shows good 
inter-rater and test-retest reliability. The MMSE is more sensitive than alternative 
measures at milder levels of disability, but is subject to sociodemographic bias. 
Scores between 10 and 26 correspond to mild to moderate dementia. 
 
2. The Nürnburger-Alters-Beobachtungs-Skala (NAB) is a measure of a patient’s 
performance at activities of daily living. The assessment exercise is completed by the 
patient’s carer and comprises 15 items, each measured on a 3 point scale. The 
scores range from 15 to 45 and an increase in score indicates a deterioration.  
 
3. The Zerssen Adjective Mood Scale (BfS: Befindlichkeitsskala) evaluates treatment 
induced changes of moods and is completed by the patient. The total score ranges 
from 0 to 56 where an increase indicates a deterioration. This scale is of particular 
interest given the high incidence of depression referred to earlier. 
 
4. The Digit Symbol Substitution Test (DSST) measures cognitive performance by 
asking the patient to copy fixed combinations of numbers and symbols. The sum of 
correct answers obtained within 90 seconds gives the score, subject to a maximum 
of 67; parallel forms being used throughout the study to avoid learning effects. A 
score decrease indicates a deterioration. 
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Other Scales Used 
 
1. The Alzheimer’s Disease Assessment Scale
17
 - cognitive subscale (ADAS-cog). This 
is an 11 point subscale of the ADAS with a maximum score of 70 (most severe). The 
ADAS-cog measures memory, orientation, attention, language and motor skills, but 
not everyday living skills. Although the scale shows good inter-rater and test/re-test 
reliability, it has been described as ‘too sensitive to change’
18
 and not conveying a 
sense of clinical relevance. In research terms, a difference of four points on the 
ADAS-cog is seen as significant. Seven points will show up as slight clinical 
improvement (e.g. patient recall is slightly better, a patient being able to name a few 
more objects). The overall rate of decline in patients with AD is between 6 and 12 
points per year. Deterioration is not necessarily linear and there may be marked 
variation between individuals depending on initial severity.  
 
2. A revised version of the Clinician Interview Based Impression
18
 (CIBIC plus). This 
was used by experienced clinicians independently of the ADAS-cog. The measure 
includes caregiver interview information as well as patient assessment. The CIBIC 
plus is a seven point scale which measures a patient’s global performance in 
cognitive, behavioural and functional terms and incorporates input from the primary 
caregiver. The test/re-test reliability of CIBIC plus is poor, although reliability is an 
issue for all subjective measurements. 
 
 
2.3 Pilot and Phase II Studies 
 
The pilot study, reported by Mielke et al.,
6
 was primarily aimed at assessing the effects of 
propentofylline on the regional cerebral glucose metabolism (rCGMRGI) of patients with 
VaD over a three month period. The trial was double-blind, placebo controlled and 
randomised. Patients, aged between 40 and 85, with a clinical diagnosis of VaD according 
to the Diagnostic and Statistical Manual of Mental Disorders, Revised, Third Edition (DSM-
III-R), were included in the trial. Patients were mildly to moderately demented with an 
Hachinski score of seven or more and MMSE greater than 15 and less than 25. Clinical 
treatment effects were assessed as secondary outcomes, using the MMSE, the memory 
task, the Digit Symbol Subtest (DSST) and the fragmented picture task. Statistically 
significant results were reported, in which patients treated with propentofylline did better, 
compared with those on placebo in respect of the measures of metabolic function. For the 
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neuropsychological measures, the MMSE and DSST showed a trend improvement for those 
on propentofylline versus placebo which was not statistically significant, whilst the 
fragmented picture test showed a statistically significant improvement (p<0.05). 
 
The Phase II study
8 
was a three month multi-centre, double blind, placebo controlled parallel 
group trial, aimed at assessing the effects of propentofylline on cognition or disease 
progression. The primary efficacy measure was defined as improved performance on the 
GBS scale and improvement in at least two of eight psychometric tests. Patients aged 55 to 
80, with a diagnosis of dementia according to the DSM-III-R were included in the trial. 
Patients were mildly to moderately demented with MMSE greater than 15 and less than 25 
and a maximum GBS score of 14. The GBS and MMSE scores improved over three months 
for both treatment and placebo groups, the improvement, however, was greater in the 
propentofylline group. The difference in improvement in GBS score ranged between 4 and 
16 for different MMSE sub-groups on a scale of 156. The difference in improvement in 
MMSE was 1.3 on a scale of 30. Both these differences were statistically significant, but are 
modest, and the clinical relevance is very doubtful. No benefits in terms of the psychometric 
assessments between the two groups were found and, thus, the efficacy of propentofylline 
as defined a priori was not demonstrated. 
 
2.4 Results of Phase III Trials 
 
Three papers have been published from the Phase III programme, one trial report, 
Marcusson
9
, and two meta-analyses, Kittner
10 
and Rother.
11
 
 
The paper by Marcusson et al. details a study of 260 patients in 19 centres across seven 
European countries
9
. Generally speaking, it appears to be a well conducted study which is 
clearly written and merits serious consideration. The methods section details the different 
scoring systems used in the trials, together with background references. This is of particular 
importance since the measures appear to be obscure. Furthermore, clinically relevant score 
differences are defined a priori for each of the measures. 
 
The paper by Kittner, Rössner and Rother,
10
 all drug company employees, is a ‘meta-
analysis’ of four unreferenced studies. There are a number of methodological criticisms of 
this paper.  The statistical convention when undertaking a meta-analysis of several trials is 
to pool the results, e.g. in terms of odds ratio or relative risk from the individual trials, thus 
allowing the final summary measure to be weighted according to the size and variability from 
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the individual studies. The analysis presented in the Kittner paper essentially ignores the 
separate studies, does not test for homogeneity of the studies, and effectively pools all 
patients into one big trial; this gives equal weight to all studies and is not considered good 
practice.
19
  
 
The number of patients excluded and the details of the exclusion criteria in each of the trials 
is not given. The paper states that ‘patients with at least one post baseline assessment per 
variable are included in each analysis’. It is unclear whether or not this contradicts the 
statement that the analysis was on an intention to treat basis. The paper claims clinically 
relevant treatment differences, but does not define these a priori. A sub-group analysis is 
undertaken for patients with AD and VaD, but it should be noted that the classification of 
these conditions is inconsistent between the four trials. Specifically, the Hachinski scale 
provides a narrower definition of multi-infarct dementia whilst the NINDS-AIREN 
classification also includes single infarct and acute onset dementias. 
 
The paper by Rother et al.
11
 presents a review of the Phase III programme, references the 
trial reported by Marcusson et al. and confirms the remaining three trials as unpublished. 
The sub-group analysis for VaD and AD is repeated. Additional details of one of the subject 
trials, ascribed to Karlsson et al., are given, and an eight week withdrawal study undertaken 
as an extension to this trial is discussed and results presented. The analysis in this paper is 
subject to the same methodological criticisms as the Kittner analysis. 
 
The available information on the four studies within the Phase III programme is summarised 
in Table 4. 
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Table 4 Summary of the Phase III Programme 
TRIAL European Propentofylline Study Group
9
 - Meta-
analysis Study II
10
 
Karlsson (Unpublished) - Meta-
analysis Study IV
10
 
Meta-analysis Study I
10
 Meta-analysis Study III
10
 
DATE 1991- 93 1994-96 Unknown Unknown 
DESIGN Multinational, randomised, placebo controlled, 
double-blind trial 
Multinational, double-blind, 
placebo controlled, randomised 
Double-blind, placebo controlled, randomised 
PATIENT NUMBERS 260 patients 
129 propentofylline 
131 placebo 
550 patients 
265 propentofylline 
285 placebo 
293 patients 170 patients 
INCLUSION CRITERIA 
Mild to moderate AD or VaD (DSM-III-R). MMSE 1525, dementia present for at least 6 months. 
Classification: 
Alzheimer’s disease 
Vascular dementia 
 
DSM-III-R 
Hachinski score 
 
NINCDS/ADRDA 
NINDS/AIREN 
 
DSM-III-R 
Hachinski score 
 
NINCDS/ADRDA 
NINDS/AIREN 
EXCLUSION CRITERIA 
 
Other significant medical conditions; history of 
psychiatric, neurological and/or other cerebral 
diseases; concomitant treatment to improve 
cerebral blood flow which could not be stopped 
prior to screening; participation in another clinical 
trial within 3 months of study.   
Secondary dementia, previous and concomitant diseases and medications interfering 
with diagnosis or interpretation of results. Limited details only are available from the 
Meta-analysis.
9
 
 
DOSAGE 3 x 300 mg daily 
PRIMARY EFFICACY 
VARIABLES 
GBS (clinician), CGI global change (clinician), SKT (psychologist). 
SECONDARY ENDPOINTS MMSE, DSST, NAB, BfS MMSE (clinician), NAB (caregiver) 
STUDY DURATION 3 months washout 
12 months treatment 
48 weeks  
8 weeks withdrawal phase 
6 months 12 months 
WITHDRAWAL AND 
ADVERSE EVENTS 
305 patients screened, 44 excluded. 1 patient 
randomised to propentofylline, but did not take 
medication. 
Number of patients excluded not available. 
 
Total withdrawal 
Due to adverse events 
Propentofylline 
43/130 (33%) 
11/130 (8%) 
Placebo 
30/131 (22%) 
5/131   (3%) 
Overall  - Propentofylline 
               25% 
               N/A 
Placebo  
19% 
N/A 
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Global function 
From the Marcusson trial,
9
 the mean total GBS score for the propentofylline group showed a 
slight improvement between baseline and 12 months; the placebo group, however, showed 
a decline in condition over the same period, see Figure 1. The difference in mean change 
from baseline was statistically significant in both the Marcusson trial and the meta-analysis, 
see Table 5. The Marcusson trial alone showed a difference of -4.9 (±3.8), whereas the 
meta-analysis showed a difference of only -2.5 (±1.5). These are both less than the clinically 
relevant difference of six points quoted in the Marcusson paper. The magnitude of the 
change relative to the full range of the scale is also highlighted in Figure 1. 
 
The CGI (item ii) score measures the change in global function since the previous visit. The 
Kittner meta-analysis, however, only gives the difference in scores for each patient group. In 
the Marcusson trial, both the propentofylline and placebo group showed an improvement in 
condition between each visit. However, the treatment group showed greater improvements 
at all points, see Figure 1. The meta-analysis claimed a statistically significant change in 
scores of -0.2 (±0.2) at the three and six month points and a change of -0.4 (±0.2) at 12 
months. See Table 5. These are all less than the clinically relevant difference of 0.5 points 
quoted in the Marcusson trial. The Marcusson trial did show a clinically relevant change of  
-0.9 (±1.1) at 12 months, but this was not statistically significant. The magnitude of this 
change relative to the full range of the scale is also highlighted in Figure 1. 
 
Cognitive function 
The mean total SKT score, from the Marcusson trial,
9
 for both groups showed an 
improvement at the three month timepoint. This improvement was maintained in the 
propentofylline group at 12 months, whilst the placebo group declined to the baseline levels; 
see Figure 2. The difference in mean change from baseline at 12 months was statistically 
significant in both the Marcusson trial and the meta-analysis. The Marcusson trial showed a 
difference of -1.4 (±1.0), whereas the meta-analysis showed a difference of -0.8 (±0.5). See 
Table 4. These are both less than the clinically relevant difference of four points quoted in 
the Marcusson trial. As before, the magnitude of the change relative to the full range of the 
scale is highlighted in Figure 2. 
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Figure 1  Effect of Propentofylline on Global Function (data from Marcusson
9
) 
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Notes:  
1. The results are from the Marcusson trial and in all cases the benefits in favour of 
propentofylline were greater than the benefits shown in the meta-analyses. 
2. The graphs on the left show the mean change from baseline for the placebo and 
propentofylline patient groups, for the two scales. 
3. The graphs on the right show how the changes in score over the trial period compare with the 
overall range of the assessment scales. 
4. The CGI(ii) scale has a range of 0-7 for the change between visits - thus the range of 
 achievable change  over three visits is 21 points. 
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The SKT measure has been reported to correlate well with the ADAS-cog assessment 
scale.
15  
A treatment difference of 1.7 on the SKT scale is quoted as being equivalent to a 
change of 3.4 points on the ADAS-cog scale. In addition, the results from the two studies 
reported in the conference posters
12,13
 showed a difference of approximately 1.5 points on 
the ADAS-cog  scale. As mentioned above, a difference of four points on the ADAS-cog 
scale has been defined as significant in research terms and a change of seven points would 
show up as a slight clinical improvement. 
 
From the Marcusson trial, the mean total MMSE score for the propentofylline group showed 
an improvement between baseline and 12 months. However, the placebo group showed a 
decline in condition over the same period; see Figure 2. The difference in mean change 
from baseline was statistically significant in both the Marcusson trial and the meta-analysis. 
The Marcusson trial showed a difference of 1.2 (±1.1), whereas the meta-analysis showed a 
difference of 0.7 (±0.5); see Table 5. The magnitude of the change relative to the full range 
of the scale is highlighted in Figure 2. 
 
Activities of Daily Living 
The mean total NAB score, from the Marcusson trial, for both treatment groups showed a 
decline in condition throughout the course of the study, see Figure 3. The deterioration was 
greater, however, in the placebo group. The difference in mean change from baseline was 
statistically significant in both the Marcusson trial and the meta-analysis. The Marcusson 
trial showed a difference of -1.2 (±1.0), whereas the meta-analysis showed a difference of 
only -0.4 (±0.4).  
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Figure 2 Effect of Propentofylline on Cognitive Function (data from Marcusson
9
) 
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Notes:  
1. The results are from the Marcusson trial and in all cases the benefits in favour of 
propentofylline were greater than the benefits shown in the meta-analyses. 
2. The graphs on the left show the mean change from baseline for the placebo and 
propentofylline patient groups, for the two scales. 
3. The graphs on the right show how the changes in score over the trial period compare with the 
overall range of the assessment scales. 
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 Table 5 Difference in Change (propentofylline versus placebo) from Baseline at 
Final Visit (12 months / 48weeks) 
Score Disease Clinically Meta EPSG
Range Progression Relevant 
Difference
Analysis 
Kittner
p Marcusson p
Population 1,273 260
GBS 0 - 156 Increase 6 -2.5 *** -4.9 ***
Clinician (-4.1, -1) (-8.6, -1)
CGI (ii) 0 - 7 Increase 0.5 -0.4 *** -0.9 NS
Clinician (-0.6, -0.2) (-2, 0.3)
SKT 0 - 27 Increase 4 -0.8 *** -1.4 **
Psychologist (-1.3, -0.3) (-2.4, -0.4)
MMSE 0 - 30 Decrease 0.7 *** 1.2 ***
Clinician (0.2, 1.3) (0.1, 2.3)
NAB 15 - 45 Increase -0.4 ** -1.2 **
Clinician (-0.8, 0.1) (-2.2, -0.2)
 
 * p < 0.05;  **  p < 0.01; ***  p < 0.001 
 
Figure 3 Effect of Propentofylline on Activities of Daily Living (data from 
Marcusson
8
) 
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Notes:  
1. The results are from the Marcusson trial and in all cases the benefits in favour of 
propentofylline were greater than the benefits shown in the meta-analyses. 
2. The graphs on the left show the mean change from baseline for the placebo and 
propentofylline patient groups, for the two scales. 
3. The graphs on the right show how the changes in score over the trial period compare with the 
overall range of the assessment scales. 
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2.5 Adverse Events 
 
Propentofylline has been shown to be well tolerated, with a similar side-effects profile in both 
patients with AD or VaD. The side-effects reported were similar to those associated with the 
use of donepezil. The most frequently reported events were nausea, dizziness, headache, 
gastrointestinal pain, flushing, dyspepsia, vertigo, asthenia, loss of appetite, vomiting and 
hot flushes. These events were either associated with the pharmacological action of 
propentofylline on cerebral blood flow or are typical for xanthine derivatives. Adverse events 
were usually intercurrent and of short duration.
10 
The principle adverse events are 
summarised in Table 6. 
 
Table 6 Adverse Events in the Phase III Programme 
 Propentofylline Placebo 
Adverse events 40% 22% 
Nausea 10% 4% 
Dizziness 9% 4% 
Headache 7% 3% 
Gastrointestinal pain 5% 2% 
 
 
2.6 Conclusion on Direction of Evidence 
 
The best quality published evidence arises from the Marcusson trial. This trial, by its own 
definition of a priori criteria, fails to prove clinically relevant efficacy of propentofylline. 
 
The meta-analyses, Kittner and Rother,
10,11
 provide poorer quality evidence by reason of 
their reliance on unpublished trial data. These meta-analyses do not give a priori definitions 
of criteria for clinical efficacy yet claim to prove not only statistically significant but also 
clinically relevant benefits. The benefits shown in each assessment scale are, however, 
small in comparison to the overall scale ranges and are lower than the clinically relevant 
differences defined in the Marcusson paper. 
 
The conclusion is, therefore, that propentofylline appears to give a very modest benefit over 
a 12 month period in cognitive function, global function and in activities of daily living. These 
benefits may be statistically significant, but it is doubtful whether they are clinically relevant 
at the levels shown in the trials.  
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There is some evidence to indicate that these benefits, though marginal, may be sustained 
after withdrawal.
11
 This would suggest that the mode of action of propentofylline is not purely 
symptomatic. Therefore, there may be potential for longer-term benefits, though further 
evidence is required. 
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3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 Summary of Potential Costs and Benefits of Propentofylline 
 
Benefits 
 
1. Very modest improvement in global 
function for patients with mild to moderate 
AD and VaD. 
2. Very modest improvement in cognitive 
function. 
3. Very modest improvement in activities of 
daily living. 
4. Quality of life for patient:-  
  no evidence available. 
5. Quality of life for carers:- 
  no evidence available. 
6. Morbidity in carers:- 
  no objective evidence  
  available. 
Disbenefits 
 
1. Side-effects from treatment. 
2. Prolonged distress, especially when 
insight is preserved. 
 
Savings 
 
1. Possible savings made in the NHS (e.g. 
by delayed hospital entry) - no empirical 
evidence available. 
2. Possible savings in reduced need for 
nursing/residential home care - no 
empirical evidence available. 
3. Possible savings in other areas of society 
(e.g. reduction in benefits, reduction in 
home care required) - no empirical 
evidence available. 
4. Increased earnings by patients or carers - 
no quantitative evidence available. 
Costs 
 
1. Cost of the drug 
Not known - possibly in the region of 
£350 per annum
5
 @ 300mg 3 times daily. 
2. Possible cost due to side-effects 
(hospitalisation, non-hospitalisation) - 
no evidence available. 
3. Increased cost of diagnosis and 
assessment. 
4. Increased costs arising from prolonged 
need for care. 
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3.2 Health Economic Studies of the New Drugs for Dementia 
 
A number of health economic studies of the new dementia drugs, tacrine, donepezil and 
propentofylline have been published.
20,21 
The papers do not constitute cost-effectiveness or 
cost-benefit studies. No mortality or quality of life benefits have been demonstrated to 
accrue from the use of the drugs, hence, the measures of cost per life year gained or cost 
per quality adjusted life year gained are not appropriate. The main thrust of these studies is 
to investigate the economic impact of introducing the drugs and to demonstrate that they 
could potentially be cost-neutral or cost-saving over conventional management strategies. In 
general, a similar approach is taken in each of these papers, although they vary in 
methodological detail. The approach is outlined below: 
 
 The cost of caring for dementia patients in the different care settings is identified. 
 
 The patients in the different care settings are profiled, at a point in time, in terms of 
some measure of disease progression. Most commonly this is cognitive function as 
measured by the MMSE. 
 
 RCT evidence is used to show the effectiveness of the drug in relation to disease 
progression. This is usually in terms of the difference in mean change from baseline 
in MMSE score and is usually over a relatively short period of time.   
 
 The long-term disease progression under conventional management is described in 
terms of the changes in MMSE over the course of the disease, either over an 
arbitrarily long time horizon or to death. The RCT evidence for the drug is then 
superimposed on this to model the long-term effects of drug therapy on MMSE 
progression. 
 
 A causal relationship between cognitive function, as measured by the MMSE, and 
the care setting is then assumed. This is used as the basis for a model of long-term 
resource usage and costs. A linear regression model of cost against MMSE score is 
proposed in the propentofylline study, whilst a Markov, state transition model, is 
developed in the study on donepezil, and a decision analytic method is used in the 
tacrine study. 
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 The long-term care requirements and, thus, costs over the defined time period, are 
modelled for a cohort of patients starting with a range of MMSE scores and in a 
range of care settings with and without drug therapy. 
 
3.3 Economic Impact of Introducing Propentofylline for the Treatment of Dementia 
in Sweden 
 
The propentofylline study
5
 claims to show that propentofylline will be cost saving when used 
in conjunction with conventional packages of care. These claimed savings result from delays 
in transition to more costly forms of care throughout the period of disease progression. 
These delays are assumed to arise as a result of the marginal benefits in cognitive function. 
 
The baseline result claims an annual saving per patient ranging from SEK 5,500 to SEK 
6,400 (approximately £370 to £430) over the first four years of treatment. This gives a total 
net saving per patient over the full duration of disease progression of approximately SEK 
14,000 (£930). This is estimated to be 3.8% of care costs for mild to moderate dementia 
patients and 0.5% of the cost for all patients. 
 
A one-way sensitivity analysis for model parameters is undertaken, supported by a number 
of scenario analyses which investigate the effects of varying some of the assumptions within 
the model. It should be noted that no multi-way sensitivity analysis has been undertaken to 
obtain an overall assessment of the effect of uncertainty within the model.   
 
Accepting the assumptions within the model, the positive results are sensitive to variation in: 
 
 efficacy of propentofylline, in terms of deterioration in MMSE prevented. (Note the 
lower 95% confidence interval of efficacy from the Kittner meta-analysis leads to a 
net cost increase from propentofylline); 
 
 the regression model coefficients; that is the cost per one point change in MMSE; 
 
 the assumption that mortality is not affected; 
 
 the price of propentofylline. 
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The key to this paper, however, is the assumption of a causal relationship between cognitive 
function, as measured by the MMSE, and the resource usage or cost.  
 
The paper takes a snapshot of the dementia population at a point in time and undertakes a  
linear regression analysis to investigate the relationship between MMSE score and cost. It 
finds that there is a correlation between cognitive function and the need for more intensive 
(and costly) care; that is, patients with more severe dementia need higher levels of support. 
The subsequent assumption that small variations in the MMSE will lead to corresponding 
changes in care requirements and, therefore, costs, is the weakest link in the argument and 
not supported by objective evidence or independent clinical judgement. 
 
In order to show a benefit from drug treatment, it needs to be proved that the marginal 
cognitive benefit will affect the need for particular levels of care and that the transition 
between care settings will consequentially be delayed. In practice, the decision to move 
from, for example, home care to residential care or residential care to nursing care is 
determined by a large range of diverse factors both medical and social. These include: 
 
 presence of a partner or other carer; 
 
 mobility; 
 
 ability to wash, dress and prepare food; 
 
 availability of alternative support functions; 
 
 level of confusion or cognitive function. 
 
In addition, there is likely to be a high level of inertia against moving between care settings. 
Thus, for example, an existing patient who is living and being supported in his/her own 
home is likely to be maintained there for as long as possible, whereas a new patient 
presenting with similar symptoms may be referred to residential care.  
 
On a more technical, but related note, the central concepts in this paper are the linear 
regression of MMSE and costs of care. The reporting of this modelling is incomplete, 
however: 
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 It is not clear from the methods or the results section of the paper what factors were 
considered for inclusion in the model. It reports only that sex was considered for 
inclusion, but did not improve the fit of the model. This implies that other potentially 
important factors, such as, the presence of a partner or other carer, mobility or 
activities of daily living were not considered. 
 
 The regression method used - stepwise, forwards or backwards - was not reported. 
 
 The quality of fit of the model is not adequately described, only the adjusted r
2
 value 
being given. The r
2
 statistic is 0.42 indicating that the MMSE score explains 42% of 
the variation in costs. Given the central role of the model, the F statistic for the 
MMSE score giving the statistical significance of this factor should be given. 
Furthermore, and perhaps more importantly, the testing of the linearity assumptions 
should be addressed explicitly. 
 
With these reservations, the r
2
 statistic indicates a reasonable fit of the regression model. 
The criticism is not that the model does not fit the data, but rather that the quality of fit 
means that caution should be used in interpreting the conclusions from the model. When the 
small scale of the cognitive benefits of propentofylline, as measured by the MMSE score, is 
taken into account, this caution should be redoubled.  
 
Thus, in the light of these issues concerning the assumptions underlying the model, the fit of 
the model and the small differences in MMSE score being used with the model, there is 
grave concern that the cognitive benefits of propentofylline, which have little clinical 
relevance, would lead to delays in transition between care settings and the consequent cost 
reductions claimed.  
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
These are: 
 
1. Not to purchase propentofylline and to review the situation in the light of further 
research evidence becoming available on this and other drugs for dementia. 
 
2. To support the purchasing of propentofylline only within appropriate RCTs and other 
studies designed to answer specific questions in relation to the use of this drug. 
 
3. To purchase propentofylline within an agreed protocol defining selection and 
discontinuation criteria for the drug for a defined group of patients. 
 
4. To support open prescribing of propentofylline for all patients with mild to moderate 
dementia for whom it is judged appropriate by clinicians specialising in the mental 
health care of older adults.  
 
5. For health authorities to recommend appropriate research into this class of drugs to 
answer the questions on cost and benefits outlined in this report. 
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5. DISCUSSION AND CONCLUSIONS 
 
5.1 General 
 
There is limited published evidence that propentofylline produces a very modest benefit in 
global and cognitive function in patients with mild to moderate AD or VaD. While the benefit 
from drug therapy is statistically significant, there are methodological concerns regarding the 
meta-analysis of the four trials.  Furthermore, the modest benefit reported fails to achieve 
clinical relevance where clinically relevant differences have been defined.  
 
It is recognised that the Phase III programme was initiated prior to the widespread 
availability of the ADAS-cog instrument. However, the lack of local experience with all of the 
assessment scales used, excepting the MMSE, means that it is difficult to interpret the 
clinical implications of the published results. In the Marcusson paper, where results have 
been interpreted in terms of the ADAS-cog scale, and in the trials reported in conference 
posters, the ADAS-cog results are similarly very modest and certainly less than accepted 
clinically relevant thresholds.    
 
Propentofylline has a different pharmacological basis for use in dementia from the two 
existing drugs, donepezil and rivastigmine. The latter are both cholinesterase inhibitors 
which have predominantly central neurotransmitter-related effects with limited peripheral 
activity, hence minimising toxicity. Propentofylline is, however, a phosphodiesterase inhibitor 
(cf. theophylline and caffeine) and an adenose re-uptake inhibitor. The relative and absolute 
significance of these activities in dementia is not fully substantiated. The results from the 
eight week withdrawal study of propentofylline suggest that it has a functional rather than 
purely symptomatic effect. 
  
Practical difficulties are foreseen in monitoring the effectiveness of propentofylline in clinical 
practice in patients with VaD. It is accepted that nearly all patients with AD show a 
progressive deterioration and that it is theoretically possible to monitor patients, once they 
have started treatment, to identify those whose rate of deterioration seems to be slowing, 
plateauing or showing an improvement. With patients with VaD, however, there is great 
variability in the course of the illness and there may be long periods of time during which the 
patient is stable. Therefore, it is only those patients who are showing a convincing 
improvement over a three month period that one can confidently classify as responders. If 
the improvement is going to be as little as one point on the MMSE scale, then the sensitivity 
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and reliability of this test in serial measurements is an important issue. Futhermore, these 
issues have important implications when considering the practicalities of defining protocols 
for use and withdrawal of drug therapy. 
 
The clinical evidence for propentofylline comes from one fully published RCT, two meta-
analyses, including three further unpublished RCTs, and a number of, as yet, unpublished 
conference presentations. Thus, there is substantial concern that much of the evidence for 
propentofylline arises from unpublished trials.  
 
Furthermore, it should be noted that the benefits shown in the published trial (Marcusson, et 
al.
9
) are approximately twice the size of the benefits shown in the meta-analysis, see Table 
4. This raises a question over the size and statistical significance of the benefits shown in 
the remaining unpublished trials, covering over 800 patients, which must certainly have been 
less than the already modest benefits shown in the meta-analysis and may well, from the 
figures available, have been neither statistically, still less clinically, significant. It is 
recognised that there may well be valid methodological reasons for these differences. 
Therefore, the importance of full publication of individual trial methodology and results is 
reiterated. 
 
A linear regression model has been claimed to demonstrate that propentofylline is likely to 
lead to a reduction in the cost of providing care and support to the dementia population and 
that this reduction would offset the additional drug costs. There are important 
methodological criticisms of this modelling exercise, principally, in the assumption that very 
modest benefits in cognition and global function will lead to corresponding changes in the 
support costs. Whilst it is undoubtedly true that only relatively small changes in care 
requirements would be required to offset the drug costs, the modelling exercise does not 
constitute substantial evidence. In order to address the economic issues of using 
propentofylline, further research is required either to validate the assumptions within the 
model or directly to assess the cost and consequences of therapy in an economic analysis 
alongside a clinical trial. 
 
5.2 Recommendations for Further Research 
 
Further research is required to examine the costs and consequences of the use of 
propentofylline. In particular, research is needed to examine whether there is any reduction 
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in the use of hospital, nursing home or community care services. Intermediate evidence 
validating the assumptions within the economic modelling would also be useful. 
 
The impact on the health and quality of life of carers should be examined further, possibly 
using validated measures, such as, the Care Givers Activity Scale. 
 
Further work is required on the development of validated and reliable assessment scales for 
measuring the quality of life of patients with dementia. 
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